



# Case Study Presentation: **Biocon's** **Biotechnology** **Innovation**

Scientific  
Report  
Template

01



**BY:**

JAGRITI CHHABRA

# CONTENTS

---

**Title Slide**

**Part 1**



**Introduction**

**Part 2**



**The  
Innovation –  
Biosimilar  
Insulin**

**Part 3**



**Novel  
Biologics  
Portfolio**

**Part 4**



# contents

*part 5*  
Applications

---

*part 6*  
Market Impact

---

*part 7*  
Competitive Advantage

---

*part 8*  
Challenges

---

*part 9*  
SWOT Analysis

---

*part 10*  
Future Outlook

---



# Title Slide

- *Biocon's Biotechnology Innovation: Biosimilars & Biologics*
- *Subtitle: Affordable Access to Advanced Therapies*
- *Your name / course / date*

01

01



# Introduction

---

- BIOCON: INDIA'S LARGEST BIOPHARMACEUTICAL COMPANY
- FOCUS ON BIOSIMILARS, BIOLOGICS, GENERICS
- INNOVATION: AFFORDABLE INSULIN & MONOCLONAL ANTIBODIES

02

02





# **The Innovation – Biosimilar Insulin**

- BIOCON DEVELOPED BIOSIMILAR INSULINS (INSULIN GLARGINE, INSULIN ASPART)
- FIRST INDIAN COMPANY TO GET US FDA APPROVAL FOR BIOSIMILAR INSULIN
- ENABLES AFFORDABLE DIABETES CARE GLOBALLY

**03**

**03**



# Novel Biologics Portfolio

- ONCOLOGY: TRASTUZUMAB (BIOSIMILAR TO HERCEPTIN)
- IMMUNOLOGY: ADALIMUMAB BIOSIMILAR
- DIABETES: GLP-1 PEPTIDE GENERICS
- DIFFERENTIATED OFFERING ACROSS ONCOLOGY, IMMUNOLOGY, DIABETES



04

04

# Applications




**- Diabetes  
care**

**- Cancer  
treatment**

**- Immunology**

**- Global  
healthcare**





# Market Impact

---

**1. Biosimilar insulins & GLP-1 peptides**

**2. Expanded presence in US, EU, Japan**

**3. Revenue from biosimilars contributes ~45% of Biocon's total**



# Competitive Advantage



**Cost-effective  
R&D in India.**



**Strategic  
partnership.**



**Strong regulatory  
track record.**



**121+** MYLAN,  
VIATRIS

**131+** PFIZER

**121+** FDA, EMA  
APPROVALS

# Challenges

**1. - Regulatory hurdles.**

**2. - Pricing pressures.**


**3. - Patent litigation.**

**4. - High R&D costs.**

---



# SWOT Analysis






# Future Outlook

- **Expansion into novel biologics & cell therapies**




- **Strengthening oncology & diabetes portfolio**




- **Aim: Become top 10 global biotech firm**


# Case Study Highlight



**- Biocon's biosimilar insulin reduced treatment cost by 30-40% compared to branded versions**



**- Impact: Millions of patients in India, US, EU gained access to affordable diabetes care**





# Conclusion



- Biocon's innovation in biosimilars & biologics transformed global healthcare

- Applications: Diabetes, cancer, immunology

- Market impact: Affordable access, global expansion

- Challenges: Regulation, competition, pricing

- Future: Novel biologics, cell therapies, global leadership





# THANKS FOR WATCHING

---



by:

JAGRITI CHHABRA

01